BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, June 4, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 6, 2012
View Archived Issues
Rilotumumab does not improve efficacy of combination therapy in prostate cancer trial
Read More
Cixutumumab and ramucirumab studied in metastatic castration-resistant prostate cancer
Read More
FDA grants orphan drug status to Del Mar Pharmaceuticals product
Read More
Magnetic resonance techniques detect metabolic biomarker of low-grade glioma
Read More
Intellect Neurosciences provides pipeline update
Read More
Novo Nordisk completes phase I trial of novel oral insulin
Read More
Prima BioMed begins enrollment in CANVAS study
Read More
Merck KGaA claims new ALK5 inhibitors
Read More
Brazilian university patents new products with anticancer potential
Read More
Bayer Schering designs novel activators of soluble guanylate cyclase
Read More
OGX-427 shows signs of efficacy in phase II trial
Read More
Phase II trial assesses RO-4929097 in prostate cancer
Read More
Alpharadin available through new expanded access program
Read More
Pfizer designs novel liver X receptor modulators
Read More
Phase II GFT-505 study meets all efficacy objectives
Read More
Clinuvel Pharmaceuticals files MAA for erythropoietic protoporphyria treatment
Read More
Novel beta1-adrenoceptor ligands synthesized in U.K.
Read More
Novel PI3K inhibitors disclosed by Novartis
Read More
FDA accepts IND for Ziopharm product
Read More
FDA lifts partial clinical hold on hepatitis C therapy
Read More
FDA advisory committee sets date to review Marqibo NDA
Read More
Biogen Idec and Sobi release details of revised hemophilia program agreement
Read More
Oryzon choses drug candidate to begin preclinical testing for Huntington's disease
Read More
